Chronic widespread pain in spondyloarthritis

  • F. Atzeni | atzenifabiola@hotmail.com Rheumatology Unit, L. Sacco University Hospital, Milan, Italy.
  • L. Boccassini Rheumatology Unit, L. Sacco University Hospital, Milan, Italy.
  • M. Di Franco Rheumatology Unit, Department of Internal Medicine and Medical Specialties, La Sapienza University, Rome, Italy.
  • A. Alciati Hermanas Hospitalarias, FoRiPsi, Department of Clinic Neurosciences, Villa San Benedetto Menni, Albese con Cassano (CO), Italy.
  • A. Marsico Reumatology Unit, S.S. Annunziata Hospital, Taranto, Italy.
  • M. Cazzola Rehabilitation Unit, Busto Arsizio Ospedale di Circolo, Presidio Ospedaliero di Saronno (VA), Italy.
  • G. Cassisi Rheumatology Branch, Specialist Outpatients Department, Belluno, Italy.
  • P. Sarzi-Puttini Rheumatology Unit, L. Sacco University Hospital, Milan, Italy.

Abstract

The pain associated with spondyloarthritis (SpA) can be intense, persistent and disabling. It frequently has a multifactorial, simultaneously central and peripheral origin, and may be due to currently active inflammation, or joint damage and tissue destruction arising from a previous inflammatory condition. Inflammatory pain symptoms can be reduced by non-steroidal anti-inflammatory drugs, but many patients continue to experience moderate pain due to alterations in the mechanisms that regulate central pain, as in the case of the chronic widespread pain (CWP) that characterises fibromyalgia (FM). The importance of distinguishing SpA and FM is underlined by the fact that SpA is currently treated with costly drugs such as tumour necrosis factor (TNF) inhibitors, and direct costs are higher in patients with concomitant CWP or FM than in those with FM or SpA alone. Optimal treatment needs to take into account symptoms such as fatigue, mood, sleep, and the overall quality of life, and is based on the use of tricyclic antidepressants or selective serotonin reuptake inhibitors such as fluoxetine, rather than adjustments in the dose of anti-TNF agents or disease-modifying drugs.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2014-06-06
Info
Issue
Section
Reviews
Keywords:
Spondyloarthritis, Fibromyalgia, Prevalence, Disease activity, Ankylosing spondylitis disease activity score, Bath ankylosing spondylitis disease activity index.
Statistics
  • Abstract views: 1433

  • PDF: 853
How to Cite
Atzeni, F., Boccassini, L., Di Franco, M., Alciati, A., Marsico, A., Cazzola, M., Cassisi, G., & Sarzi-Puttini, P. (2014). Chronic widespread pain in spondyloarthritis. Reumatismo, 66(1), 28-32. https://doi.org/10.4081/reumatismo.2014.761

Most read articles by the same author(s)